Clinical Trial Update: Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 study comparing intravenous ceftolozane/tazobactam to piperacillin/tazobactam in ventilator-associated pneumonia was terminated; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ventilator-associated Pneumonia

Drugs mentioned

• Ceftolozane/Tazobactam (ceftolozane/tazobactam)
• Piperacillin/tazobactam (Piperacillin/tazobactam)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Ventilator-Associated Pneumonia (VAP) | Phase 3 | Status: TERMINATED | Results posted: 2015-06-15